Healthcare U.S. Community
Our community narratives are driven by numbers and valuation.
Healthcare U.S. Investing Ideas
Hims & Hers Health aims for three dimensional revenue expansion
In a nutshell: Hims & Hers’ recent investments are overlooked by investors, but they signal strongly revenue growth is not slowing down. The Starting Point Some analysts have low estimates for future revenue growth (approx.Read more
UNH stands out as a very low-risk investment.
Valuation: UnitedHealth Group’s new CEO, Stephen Hemsley, has reaffirmed confidence in the company’s ability to return to its long-term earnings growth target of 13%–16% by 2026. Despite recent headwinds—including elevated Medicare Advantage costs, a major cyberattack, and leadership transitions—Hemsley emphasized that these challenges are manageable and well within the company’s capacity to address.Read more
Profit margins at UNH are expected to climb by 4.042% suggesting robust financial health
UnitedHealth: Margins Poised for Growth UnitedHealth Group (NYSE: UNH) continues to demonstrate financial strength and operational efficiency, with profit margins projected to rise by 4.042% in the coming period. This anticipated expansion highlights the company’s robust business fundamentals and disciplined cost management strategy.Read more
La tesis es que el castigo fue exagerado y los márgenes pueden recuperarse en 2026.
Aseguradora líder en Medicaid y Obamacare; retiró su guía 2025 por costos médicos más altos y la acción cayó ~40 %. La tesis es que el castigo fue exagerado y los márgenes pueden recuperarse en 2026.Read more
Why CVS’s Valuation Signals Opportunity
CVS Health has just faced a stock decline of about 10% after its preliminary Q3 earnings miss, which made the entire market aware. The decline is contributed largely to a $1.1 billion charge connected with its Medicare and Individual Exchange businesses and a whopping $1.2 billion restructuring charge for store closures.Read more
LifeMD is a diamond in the making
Telehealth is the future of healthcare in america and around the world. Most people don’t want to wait hours in the hospital or even weeks for an appointment.Read more
Intervalo de avaliação de $2,06 a $3,80. Insiders compraram recentemente a $2,86
No modelo DCF a avaliação atual varia entre $2,06 com WACC 9,31% com taxa terminal de 2% (conservadora) O modelo de avaliação por comparação com os pares aponta para $2,29 O modelo Simply Wall Street com as mesmas premissas que utilizado no moderno DCF: WACC= 9,31% avalia a ação em $3,80 O PEG fwd aponta para PE =69X para 2025 e taxa crescimento EPS a médio prazo de 40% está um pouco sobrevalorida PEG=1,74. Para PEG=1 a ação estaria a cotar no 2,80 o que coincide com a cotação atual.Read more
Quality at a Premium. A time to watch, not to buy?
Key Takeaways Consistent revenue growth, strong profitability, and a pristine balance sheet position Addus for sustained disciplined acquisitive growth and improved operational efficiency. The company's business model is resilient and defensive against cyclical downturns, making it a safe haven in times of economic uncertainty.Read more
NHC Analysis: Quality at a Good Price. A Golden Opportunity?
Key Takeaways A highly diversified business model and a pristine balance sheet position National HealthCare Corporation for sustained, profitable growth. The company's current low valuation is a result of a short-term drop in net income, which we believe is temporary and creates a compelling investment opportunity.Read more
